Rep. Kathy Castor

Accelerating Access to Critical Therapies for ALS Act This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials.  The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases. The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.

Protecting Our Democracy Act This bill addresses issues involving (1) abuses of presidential power; (2) checks and balances, accountability, and transparency; and (3) election integrity and security. Specifically, regarding abuses of presidential power, the bill requires the Department of Justice (DOJ) and the President to submit to Congress specified materials relating to certain pardons, prohibits presidential self-pardons, suspends the statute of limitations for federal offenses committed by a sitting President or Vice President, prohibits the acceptance of foreign or domestic emoluments, and sets forth provisions regarding Office of Government Ethics and Office of Special Counsel jurisdiction and enforcement authority. To address checks and balances, accountability, and transparency, the bill authorizes specified actions to enforce congressional subpoenas, imposes limits on presidential declarations of emergencies, requires DOJ to maintain a log of specified communications between it and the White House, requires cause for removal of inspectors general, increases whistleblower protections, and requires a candidate for President or Vice President to provide copies of tax returns for the 10 most recent taxable years to the Federal Election Commission. To address election integrity and security, the bill requires federal campaign reporting of foreign contacts, makes various changes to requirements concerning foreign donations to political campaigns and candidates and foreign contributions to online electioneering communications, prohibits distribution of materially deceptive audio or visual media prior to an election (i.e., deepfakes), and establishes a program to support states and localities transition to ranked choice voting systems.

Humane Cosmetics Act of 2021 This bill generally prohibits animal testing in the evaluation of cosmetic products, and it prohibits the sale or transport of cosmetics developed using animal testing, subject to civil penalties. These prohibitions begin one year after enactment. The bill specifies exceptions to these prohibitions, including if such animal testing (1) is conducted outside the United States to comply with a foreign regulatory authority; (2) is pursuant to a specified finding that there are no nonanimal alternatives to test the safety of a potentially dangerous cosmetic product or ingredient; (3) is of a product or ingredient for a drug or device subject to regulation by the Food and Drug Administration (FDA); or (4) is required for a noncosmetic purpose pursuant to a state, federal, or foreign regulatory authority. Further, no animal-testing evidence may be used to establish the safety of a cosmetic product or ingredient that is regulated by the FDA after the effective date of this bill, subject to limited exceptions.

Stillbirth Health Improvement and Education for Autumn Act of 2021 or the SHINE for Autumn Act of 2021 This bill authorizes grants and establishes other programs to improve data collection on stillbirths. Specifically, the Department of Health and Human Services (HHS) may award grants for surveillance and data collection on stillbirths, and HHS must issue guidelines for health departments and vital statistics units concerning the collection of stillbirth data. HHS must also develop educational awareness materials about stillbirths and make them publicly available. Furthermore, HHS must implement a fellowship program to provide training in perinatal autopsy pathology and otherwise support research on stillbirths and fetal autopsies. The bill also requires HHS to issue a report with educational guidelines on stillbirths and stillbirth risk factors.

Maddy summaryHRES 834 is a ceremonial resolution honoring the late Congresswoman Carrie Pittman Meek (1926-2021) for her congressional service and legacy. It commends her dedication to public service, her role as a trailblazer for Black women in politics, and her advocacy for communities in Florida. The resolution specifically recognizes her work securing hurricane relief funding after Hurricane Andrew and her service in the Florida State Senate and U.S. Congress. As a commemorative resolution, it contains no policy changes or funding provisions.

FTC Whistleblower Act of 2021 This bill provides protections and incentives for whistleblowers who disclose information about, or refuse to participate in, an activity they reasonably believe is a potential violation of any law, rule, or regulation enforced by the Federal Trade Commission. Specifically, it prohibits retaliation against whistleblowers and provides monetary incentives for information that leads to administrative or judicial actions that result in sanctions exceeding $1 million.

Promoting Resources to Expand Vaccination, Education, and New Treatments for HPV Cancers Act of 2021 or the PREVENT HPV Cancers Act of 2021 This bill reauthorizes through FY2026 and expands Department of Health and Human Services activities to educate health care providers and the public about human papillomavirus (HPV), its association with certain cancers, and the importance of HPV vaccines. Specifically, the bill (1) requires relevant educational materials to include information about both cervical cancer and other HPV-associated cancers and about the importance of HPV vaccines, including for males; (2) expands the scope of a national education campaign about gynecologic cancers to address HPV-associated cancers more broadly and target specified, at-risk populations; and (3) authorizes demonstration projects to increase knowledge and awareness of gynecologic cancers.

Maternal Vaccination Act This bill includes a focus on pregnant and postpartum individuals in existing public health activities to increase vaccination rates. First, the Centers for Disease Control and Prevention must incorporate a focus on pregnant and postpartum individuals, including by disseminating information to obstetric health care providers, into its existing public awareness campaign about the importance of vaccinations. Second, the bill expressly allows certain project grants for preventive health services to be used for activities to increase vaccination rates of pregnant and postpartum individuals (and their children).

Immunization Infrastructure Modernization Act of 2021 This bill directs the Department of Health and Human Services (HHS) to take actions to improve data sharing and other aspects of immunization information systems. These are confidential, population-based databases that maintain a record of vaccine administrations. Specifically, HHS must develop a strategy and plan to improve these systems, including systems supported by the Centers for Disease Control and Prevention; designate data and technology standards for use in these systems; and award grants to health departments and other government agencies to improve their systems. As a condition of receiving the grants, recipients must use the designated standards. However, HHS may waive this condition in some circumstances. HHS must also report to Congress on these activities.

Strength in Diversity Act of 2021 This bill establishes a program through which the Department of Education may award planning and implementation grants to specified educational agencies (e.g., local educational agencies) to improve diversity and reduce or eliminate racial or socioeconomic isolation in publicly funded early childhood education programs, public elementary schools, or public secondary schools.